$PHBI The Equity Agreement will hopefully allow Pharmagreen to move forward at a faster pace with its development of the Cannabis Biotech Complex and state of the art Greenhouse. Pharmagreen is finalizing its updated development plans to include an all-year round greenhouse operations in support of its starter plantlets sales with its CBD Dana hemp strain. The completion of the greenhouse will generate revenues for the company, while its 1 Million per month, tissue culture starter plantlet production facility, Cannabis Biotech Complex, is under construction. To date that company has done some initial site work and with the next $5 Million in the treasury the company plans to complete both, the site pre-construction phase for the Cannabis Biotech Complex and the building of the all-year round greenhouse.

Commenting on Pharmagreen’s progress, Peter Wojcik, President and CEO, stated, “We are very pleased to be working with Oscaleta, its team and its network of brokers/dealers as we move forward with our exciting business model. Furthermore, negotiating a deal that is 85% of the closing bid price is a positive for our company and reflective of NASDAQ listed companies rates.”

* Further details regarding the terms of the Equity Agreement are found in our Current Report on Form 8-K (the "Form 8-K" being filed with Securities and Exchange Commission. The description of the terms of the Equity Agreement herein are qualified in their entirety by reference to the actual terms of the Equity Agreement filed as an exhibit to the Form 8-K.

https://www.otcmarkets.com/stock/PHBI/news/Ph...?id=245917